Maastricht

Symposium sessions, workshops and round tables

Please find below a list of provisional titles for sessions accepted by the Scientific Program Committee, including the name of the submitter.

Safety

  • Symposium: Flexible, efficient and performance-driven in-house method validation responding to current regulatory challenges for identifying human thyroid disruptors – Submitted by: Sandra Coecke, European Commission Joint Research Centre
  • Symposium: Application of an in vitro testing battery for developmental neurotoxicity assessment in a regulatory context – Submitted by: Anna Bal-Price, European Commission Joint Research Centre
  • Workshop: Validation redefined: needs and opportunities for the validation of (r)evolutionary non-animal approaches for chemical safety assessment – Submitted by: Janine Ezendam, National Institute for Public Health and the Environment
  • Symposium: AOPs, MOAs, and KCs – Mutually Informative, Not Mutually Exclusive – Submitted by: Patience Browne, OECD
  • Workshop: Modern, Mechanistic Approaches to Cancer Risk Assessment – Submitted by: Gina Hilton, PETA International Science Consortium, Ltd.
  • Symposium: Methods to enhance biotransformation capability for in vitro high throughput screening assays – Submitted by: Menghang Xia, SOT/National Center for Advancing Translational Sciences
  • Symposium: New Approach Methods in AgroChemical Development and Regulatory Decisions – Submitted by: Douglas Wolf, Syngenta Crop Protection
  • Symposium: Integrated Approach to Testing and Assessment: Occam’s razor for New Approach Methodologies in 21st Century Human Health Decision-Making – Submitted by: Jason Lambert, U.S. Environmental Protection Agency
  • Symposium: Decision making in non-animal cosmetic safety assessment – Submitted by: Paul Russell, Unilever
  • Symposium: Computational Synthesis and Integration for Systems Toxicology in the Animal-free Zone – Submitted by: Thomas Knudsen, US EPA
  • Symposium: Why and how to model the distribution of chemicals in in vitro assays for quantitative in vitro-in vivo extrapolation – Submitted by: Nynke Kramer, Institute for Risk Assessment Sciences
  • Symposium: EU-ToxRisk Guidance for New Approach Methods (NAM)-supported Read-Across Approaches – Submitted by: Bob van de Water, Leiden University/ EU-ToxRisk
  • Symposium: Alternative and predictive methods for environmental risk assessment of cosmetics – Submitted by: Véronique Poulsen, L’Oréal
  • Workshop: Lessons learned from applying non-animal skin sensitisation methods: from hazard assessment to next generation risk assessment – Submitted by: Janine Ezendam, National Institute for Public Health and the Environment
  • Workshop: Lessons Learned and Practical Considerations for the Use of In Vitro Exposure Systems to Assess Respiratory Toxicity – Submitted by: Amy Clippinger, PETA International Science Consortium Ltd.
  • Symposium: Building confidence in NexGen Risk Assessment – Submitted by: Carl Westmoreland, Unilever
  • Other: A walk through 10 years of CAAT-Europe’s highlights – Submitted by: Marcel Leist, CAAT-Europe/ University of Konstanz
  • Symposium: Promoting the use of 3Rs through partnership: EPAA – Submitted by: Zvonimir Zvonar, European Partnership for Alternative Approaches to Animal testing (EPAA)
  • Round Table: Asia: A place ripe for the development of 21st century science – Submitted by: Alokparna Sengupta, Humane Society International India
  • Symposium: Challenges of Non-Animal Approaches for Food Safety & Nutrition in the 21st Century: From Inception to Application – Submitted by: Lucie Geurts, ILSI Europe
  • Symposium: The in3 project: An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment – Submitted by: Paul Jennings, Vrije Universiteit Amsterdam

 

Ethics, Welfare and Regulation

  • Symposium: Wildlife research and the 3Rs – Submitted by: Miriam Zemanova, Centre for Compassionate Conservation, University of Technology Sydney
  • Symposium: Sharing organs and tissues to reduce the lab animal usage – Current update on existing biobanks and sharing platforms – Submitted by: Annemarie Lang, Charité-Universitätsmedizin Berlin
  • Symposium: Implementing the 3Rs in Genetically Altered animals – Submitted by: David Anderson, Commission
  • Symposium: Refinement of pain & stress assessment to enhance animal welfare in rodents – Submitted by: Nuno Henrique Franco, i3S, University of Porto
  • Symposium: Focus on Severe Suffering – Submitted by: Elliot Lilley, RSPCA
  • Round Table: “How to avoid polarization in dealing with uncertainties in public, scientific and regulatory debate” – Submitted by: Jeffrey Bajramovic, TRAIN
  • Workshop: Open Science and Transparency in Animal-Based Research – Submitted by: Paulin Jirkof, University Zurich / Laboratory Animals (Editor)
  • Dynamic session: Systematic Review, Machine Learning and Data-Driven Alternatives – Submitted by: Brett Lidbury, The Australian National University
  • Workshop: Barriers of Refinement Use in Practice – Submitted by: Cathy Schuppli, University of British Columbia
  • Workshop: Establishing a European Network of 3Rs Centers and 3Rs-Societies – Submitted by: Horst Spielmann, Freie Universität Berlin
  • Workshop: Animal Experimentation: Working Towards a Paradigm Change – Submitted by: Kathrin Herrmann, Johns Hopkins Bloomberg School of Public Health
  • Workshop: Culture of Care – a culture driven, pro-active approach towards improving standards – Submitted by: Thomas Bertelsen, Novo Nordisk
  • Workshop: The Animal Welfare Body – how are we doing? – Submitted by: Penny Hawkins, RSPCA Research Animals Department
  • Round Table: Implementing openness: promoting transparency around animal research across regions – Submitted by: Bella Williams, Understanding Animal Research
  • Round Table: “Proof in animals”: Has journal editorial policy fallen behind advances in human-based approaches? – Submitted by: Marcia Triunfol, Humane Society International
  • Workshop: Impact of policymaking in animal-free research – Submitted by: Anke Sikkema, Ministry of agriculture, nature and food quality
  • Round Table: Rigor, Relevance and Reproducibility in (animal) research: when “Science’s 3Rs” come into play – Submitted by: Nicolas Dudoignon, SANOFI R&D
  • Symposium: Implementing the 3Rs in Safety Assessment and Drug Development – Submitted by: Donna W Lee, Genentech

 

Innovative Technologies

  • Workshop: Can non-animal models identify environmental endocrine disruptors? –Submitted by: Nina Hallmark, Bayer AG
  • Workshop: “Innovative approaches for CNS research – from brain organoids to new single cell culture methods” – Submitted by: Jeffrey Bajramovic, Biomedical Primate Research Centre
  • Workshop: Diving into the scientific knowledge big data looking for alternatives – Submitted by: Marco Straccia, FRESCI
  • Symposium: Novel cell-based technologies for predicting drug-induced liver injury – Submitted by: Catherine Verfaillie, Katholieke Universiteit Leuven
  • Symposium: Emerging 3D organoid technology toward animal alternative testing – Submitted by: Yasu Kanda, National Institute of Health Sciences
  • Symposium: The Role of Artificial Intelligence in Safety and Toxicity Assessment – Submitted by: Weida Tong, NCTR/FDA
  • Symposium: Innovative technologies integrating standardised regulatory test methods: challenges and perspectives – Submitted by: Anne Gourmelon, OECD
  • Dynamic session: A Virtual Human Platform for Safety Assessment – Submitted by: Cyrille Krul, University of Applied Sciences Utrecht
  • Workshop: Using the Sematic Web for Rapid Integration of Publicly Available Biological Information – Submitted by: Holly mortensen, US EPA
  • Symposium: Scientific highlights in emulating human biology on chips – Submitted by: Uwe Marx, Tissuse
  • Symposium: Personalized medicine through human organoid models – Submitted by: Christine Mummery, Leiden University Medical Center
  • Symposium: Translational success of industrial adoption of organ-on-a-chip platforms – Submitted by: Adrian Roth, Hoffman La Roche
  • Symposium: Human Organs-on-Chips: Advancing Regulatory Science through Innovation – Submitted by: Suzanne Fitzpatrick, US Food and Drug Administration
  • Workshop: Alternatives to Fetal Bovine Serum (FBS) – Submitted by: Tilo Weber, German Animal Welfare Federation / Animal Welfare Academy
  • Workshop: Use of New approach methodologies –NAMs- to derive Point(s) of departure; opportunities and limitations – Submitted by: Gladys Ouedraogo, L’Oreal
  • Dynamic session: Organoid technology for infectious diseases: from innovation to established models – Submitted by: Dasja Pajkrt, Academic Medical Center
  • Workshop: Harnessing the power of data to improve systemic toxicity prediction: multisectorial perspectives – Submitted by: Stephane Dhalluin, L’Oreal

Disease

  • Workshop: The Scientific Validity of Replacements for Animal-Derived Antibodies – the next steps OR The Recombinant Replacement Revolution – The 3Rs of antibody development – Submitted by: Alison Gray, AFABILITY / University of Nottingham, UK
  • Symposium: Modeling the muskuloskeletal system and related disorders in vitro – Cells, scaffolds and biomechanics – Submitted by: Annemarie Lang, Charité-Universitätsmedizin Berlin
  • Symposium: Reproducibility in preclinical studies – Submitted by: Kirsty Reid, EFPIA
  • Symposium: Biomed 2.0 -Non-animal Models for Biomedical Research – Submitted by: Laura Gribaldo, EURL-ECVAM,F3 Unit,JRC,EC
  • Symposium: The role of clinical research on the understanding and treatment of diseases – Submitted by: Luisa Bastos, Eurogroup for Animals
  • Dynamic session: Remove ATT, TABST & LABST. How far away we are to global harmonization for those safety tests? – Submitted by: Laura Viviani, Humane Society International
  • Symposium: NASH, the liver disease of the 21st century? Alternative technology in the spotlights. – Submitted by: Vera Rogiers, Innovation Centre-3Rs (IC-3Rs)
  • Workshop: Application of new-approach methodologies to assess the safety of medical devices – Submitted by: Sebastian Hoffmann, seh consulting + services
  • Symposium: Reverse Translation: Maximizing clinical relevance while reducing the need for preclinical data – Submitted by: Jiri Aubrecht, Takeda
  • Workshop: Biomarker-based in vitro tools targeting early Alzheimer’s in a human relevant fashion – Submitted by: Erwin L Roggen, ToxGenSolutions BV
  • Symposium: Pharmaceutical Industry initiatives driving the 3Rs – Submitted by: Kirsty Reid, EFPIA
  • Symposium: 3Rs in vaccines – Submitted by: Denis Lambrigts, GSK
  • Symposium: 3Rs in vaccines batch release – Submitted by: Denis Lambrigts, GSK
  • Workshop: Beyond the 3Rs: Expanding the Use of Human-Relevant Replacement Methods in Biomedical Research – Submitted by: Kathrin Herrmann, Johns Hopkins Bloomberg School of Public Health
  • Workshop: Of mice and men and predictive biology: what would it take to ingrain the 3Rs in biomedical research? – Submitted by: Charu Chandrasekera, Canadian Centre for Alternatives to Animal Methods